1. Home
  2. KSS vs TSHA Comparison

KSS vs TSHA Comparison

Compare KSS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$13.07

Market Cap

1.6B

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.82

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSS
TSHA
Founded
1962
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
KSS
TSHA
Price
$13.07
$6.82
Analyst Decision
Sell
Strong Buy
Analyst Count
15
8
Target Price
$15.31
$11.63
AVG Volume (30 Days)
3.8M
2.7M
Earning Date
05-28-2026
05-06-2026
Dividend Yield
3.58%
N/A
EPS Growth
142.86
5.56
EPS
2.38
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.21
$1,152.42
P/E Ratio
$6.09
N/A
Revenue Growth
N/A
17.28
52 Week Low
$7.47
$2.21
52 Week High
$25.22
$7.30

Technical Indicators

Market Signals
Indicator
KSS
TSHA
Relative Strength Index (RSI) 38.20 65.73
Support Level $12.07 $4.39
Resistance Level $16.82 N/A
Average True Range (ATR) 0.77 0.43
MACD -0.12 -0.01
Stochastic Oscillator 1.98 57.56

Price Performance

Historical Comparison
KSS
TSHA

About KSS Kohl's Corporation

Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: